MedPath

Immunoblot, Chemiluminescence and ImmunoCap Allergen Specific IgE Evaluation of in Allergic Rhinitis Patients

Not Applicable
Completed
Conditions
Diagnoses Disease
Interventions
Diagnostic Test: Sensitization to House dust mites
Registration Number
NCT06137495
Lead Sponsor
Zagazig University
Brief Summary

In the present study the investigators assay house dust mites (HDMs) IgE in sera of allergic rhinitis patients (AR) using immunoblotting, chemiluminescence, and ImmunoCAP assays to compare between the accuracy of both immunoblotting and chemiluminescence assays, and ImmunoCAP as gold standard.

Detailed Description

All allergic rhinitits patients who were monosensitized to mixed HDMs, identified by SPT, will be subjected to complete history taking and assessment of the inclusion and exclusion criteria, performance of skin prick test and measurement of total serum IgE, measurement of specific IgE by Chemiluminescence Immunoassa, immunoblot assay and ImmunoCAP™ Phadiatop™. The patients will be followed-up for 6 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
84
Inclusion Criteria
  1. Patient consent.
  2. Patient with (18-40) years age known to be allergic rhinitis.
  3. Patient with IgE mediated allergic rhinitis (positive total IgE).
  4. Patient with positive skin prick testing and monosensitized to HDM
Read More
Exclusion Criteria
  1. Patient refusal
  2. Patients taking oral corticosteroid.
  3. Patients taking anti-IgE injections.
  4. Patients taking intranasal corticosteroid.
  5. Patient with non- IgE mediated allergic rhinitis.
  6. Patients with chronic diseases.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Allergic Rhinitis PatientsSensitization to House dust mitesHouse dust mites (HDMs) IgE in sera of allergic rhinitis patients (AR) who were monosensitized to mixed HDMs, identified by SPT, is assayed using immunoblotting, chemiluminescence, and ImmunoCAP assays to compare between the accuracy of both immunoblotting and chemiluminescence assays, and ImmunoCAP as gold standard
Primary Outcome Measures
NameTimeMethod
Reduction of serum specific IgE6 months from diagnosis to end of Follow-up period

Improvement of symptoms and signs of allergy

Conversion of SPT to negative6 months from diagnosis to end of Follow-up period

Improvement of symptoms and signs of allergy

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Zagazig University Faculty of Medicine

🇪🇬

Zagazig, Sharkia, Egypt

© Copyright 2025. All Rights Reserved by MedPath